Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P00326
UPID:
ADH1G_HUMAN
Alternative names:
Alcohol dehydrogenase subunit gamma
Alternative UPACC:
P00326; Q4PJ18; Q5WRV0; Q6LBW4; Q6NWV0; Q6NZA7
Background:
Alcohol dehydrogenase 1C, also known as Alcohol dehydrogenase subunit gamma, is pivotal in ethanol catabolism, showcasing high activity for ethanol oxidation. This enzyme's efficiency in breaking down ethanol underscores its critical role in metabolic processes.
Therapeutic significance:
Understanding the role of Alcohol dehydrogenase 1C could open doors to potential therapeutic strategies. Its central function in ethanol metabolism suggests its potential impact on conditions related to alcohol consumption.